Payment overview · 2025
General Payments
$904.97
25 reported records · 9 companies
Healthcare provider profile · identity verified
Andrew Avery, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Sports Medicine · DETROIT, MI · NPI 1255587945
Verified facts
What the public records show
CMS Open Payments records show Andrew Avery, MD received $904.97 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $280.78 | 31.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $187.56 | 20.7% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 13.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $113.25 | 12.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.10 | 6.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.32 | 5.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.69 | 5.5% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $19.33 | 2.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.94 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $904.97 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $134.19 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $116.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.46 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.10 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acetaminophen-Codeine | Acetaminophen With Codeine | 618 | 92 |
| Famotidine | Famotidine | 403 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 343 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 85 |
| Alprazolam | Alprazolam | 252 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 54 |
| Lisinopril | Lisinopril | 164 | 48 |
| Losartan Potassium | Losartan Potassium | 144 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 22 |
| Omeprazole | Omeprazole | 116 | 26 |
| Metformin Hcl | Metformin Hcl | 110 | 32 |
| Celecoxib | Celecoxib | 105 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 33 |
| Furosemide | Furosemide | 102 | 30 |
| Chlorthalidone | Chlorthalidone | 92 | 23 |
| Gabapentin | Gabapentin | 91 | 15 |
| Prednisone | Prednisone | 88 | 17 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 79 | 25 |
| Trazodone Hcl | Trazodone Hcl | 78 | 16 |
| Chlorzoxazone | Chlorzoxazone | 75 | 27 |
| Hydrocortisone | Hydrocortisone | 67 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 16 |
| Carvedilol | Carvedilol | 66 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | suppressed |
| Jardiance | Empagliflozin | 60 | 12 |
| Halobetasol Propionate | Halobetasol Propionate | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 26 |
| Simvastatin | Simvastatin | 55 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 53 | suppressed |
| Lidocaine | Lidocaine | 53 | 12 |
| Ibuprofen | Ibuprofen | 51 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 14 |
| Promethazine Hcl | Promethazine Hcl | 45 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | 11 |
| Azithromycin | Azithromycin | 37 | 20 |
| Diazepam | Diazepam | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 32 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Admelog | Insulin Lispro | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Flunisolide | Flunisolide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $904.97 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, JARDIANCE, MOUNJARO, TRELEGY ELLIPTA, TWIIST, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error